Elevated ROS levels can shift the interaction of β-catenin from transcription factor 4 (TCF4) to forkhead box O3 (FOXO3a) and thus prevents tumorigenicity in vitro and tumor formation in vivo. This evidence concerns the gene FOXO3 and neoplasm.